Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of long-term immunogenicity of a quadrivalent recombinant HPV vaccine in Chinese females aged 9-45 years
CTR20221050Phase 3Active
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Start
- May 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of CERVAVAC in human papillomavirus infection, cervical intraepithelial neoplasia (CIN), vaginal intraepithelial neoplasia (VAIN) and 2 more, sponsored by Shanghai Bovax Biotechnology Co., Ltd. Primary endpoints: Neutralizing antibody geometric mean titers against HPV 6/11/16/18 and Seropositivity rates against HPV 6/11/16/18. Started May 2022; status: active.
02
Drugs
CERVAVAC
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)vaginal intraepithelial neoplasia (VAIN)Cervical Cancer (CC)anogenital warts
Beyond the preview
Go deeper on CTR20221050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221050.